Skip To Content

Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:

  • Relevant and timely industry information
  • Medication trends, and their impact
  • Case studies, and the results of their related projects
  • Special-subject on-demand webinars

Articles and blogs 

Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.

January 14, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
January 06, 2021 · Settlement Solutions Team
To help our clients achieve the lowest possible Workers’ Compensation Medicare Set-Aside (WCMSA) allocations, Optum continually monitors the average wholesale price (AWP) of the most common medications seen in a WCMSA. The following outlines the most recent price decreases for a few of these medications. Read more...
December 21, 2020 · Lavonya Chapman, Associate General Counsel of Optum Settlement Solutions
The recently enacted Provide Accurate Information Directly (PAID) Act will make it easier to determine whether payments for claimed injuries/illness involving workers’ compensation, no-fault and/or liability claims were made by traditional Medicare and/or a Medicare Advantage (Part C) plan (MAP) and/or a prescription Part D plan (PDP) and whether they need to be reimbursed. Read more...
December 15, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
December 07, 2020 · Lavonya Chapman, Esq, RN, CMSP, Associate General Counsel, Optum Settlement Solutions
On November 12, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a Technical Alert and published version 6.1 of the Non-Group Health Plan (NGHP) Section 111 User Guide. Both note changes that will eventually impact Civil Money Penalties (CMP) involving Section 111 reporting when CMS error tolerance thresholds are exceeded. Read more...
November 24, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) authorized the use of the Lucira™ COVID-19 All-In-One Test Kit under an Emergency Use Authorization (EUA) on November 17, 2020.  This is the first at-home nasal swab test kit to detect SARS-CoV-2  the virus that causes the coronavirus disease 2019 (COVID-19). Read more...
     Next >>
Page 1 of 17

Subscribe today to receive our latest blogs, articles and more.